February 7, 2014
Protease Inhibitors Make a First Splash
The first wave of new HCV drugs arrived in the form of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), which were approved in the U.S. in 2011 for the treatment of HCV genotype 1. They have not yet been approved specifically for HIV-coinfected patients, however -- and Cox suggested that their day in the sun may be setting.
In clinical trials, boceprevir and telaprevir have both been shown to dramatically increase HCV treatment success rates in therapy-naive, HIV-coinfected patients. But they still must be taken with interferon, and both drugs have been found to exacerbate the adverse effects seen among patients taking interferon-based therapies. Between those sobering data and extensive drug-interaction concerns with HIV medications, "it's not easy to take these medications," Cox said.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|AIDS 2014 Video Blog #1: At MSM Global Forum, the Shock of Tragedy and the Road Forward|
|Coverage of AIDS 2014: The 20th International AIDS Conference|
|Zero HIV Infections When PrEP Is Taken 4 or More Times a Week|
|AIDS 2014: Julio Montaner on the Proposed 90-90-90 Strategy to Help End HIV (Video)|
|Not So Fast With That Flush: Drugs That Target HIV Reservoirs May Also Impair Killer T Cells|
|Is HIV Superinfection Unhealthy?|